A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...

Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...

Researchers at University of Tsukuba investigated the changes in the primary evaluation items in phase II clinical trials for glioblastoma, a type of brain tumor. Recently, the items have become more ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

Researchers with Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real ...